HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ: PCRX ) with a Buy and maintains $38 price target.